Form D · Biotechnology
Angarus Therapeutics, Inc.
Portola Valley, CA · CIK 0001836891
Offering snapshot reported Jul 14, 2021 · SEC filing
- Reported sold
- $11.3M Offering amount: $11.3M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2021 | Amendment | $11,316,922 | No comparison | Not reported | SEC filing |
| Jun 22, 2021 | Amendment | $9,745,976 | $1,915,538vs Mar 2, 2021 | 77 | SEC filing |
| Mar 2, 2021 | Amendment | $7,830,438 | $947,000vs Dec 29, 2020 | 56 | SEC filing |
| Dec 29, 2020 | Initial | $6,883,438 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-384604
Source: Form D, filed Jul 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Langecker | Director |
| Chih Ping Liu | Director |
| Jean Liu | Director |
| Nigel Ray | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
321 Dedalera Dr.
Portola Valley, CA, 94028
Portola Valley, CA, 94028